Promising new treatments for neovascular age-related macular degeneration
- 21 June 2006
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 15 (7), 779-793
- https://doi.org/10.1517/13543784.15.7.779
Abstract
Angiogenesis, the growth of new blood vessels from existing blood vessels, is responsible for vision loss in a variety of ophthalmic diseases. In neovascular age-related macular degeneration (AMD), the leading cause for legal blindness in many industrialised countries, abnormal blood vessels grow in the macula and cause blindness. There are a number of factors important in the angiogenic cascade but VEGF-A has been implicated in recent years as the major factor responsible for neovascular and exudative diseases of the eye. Numerous antiangiogenic drugs are in development but anti-VEGF drugs have shown great promise in treating neovascular AMD and other ocular diseases, and many of these drugs have been adopted from oncology where antiangiogenic therapy is gaining wide acceptance. For the first time in neovascular AMD, anti-VEGF drugs have brought the hope of vision improvement to a significant proportion of patients. This review provides an overview on angiogenic mechanisms, potential antiangiogenic treatment strategies and different antiangiogenic drugs with special focus on neovascular AMD.Keywords
This publication has 90 references indexed in Scilit:
- THE ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN OCULAR HEALTH AND DISEASERetina, 2005
- VEGF162, A New Heparin-binding Vascular Endothelial Growth Factor Splice Form That Is Expressed in Transformed Human CellsPublished by Elsevier ,2003
- Role of angiogenesis in tumor growth and metastasisSeminars in Oncology, 2002
- Current biology of VEGF-B and VEGF-CCurrent Opinion in Biotechnology, 1999
- A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinasesThe EMBO Journal, 1999
- Solution structure of the heparin-binding domain of vascular endothelial growth factorStructure, 1998
- Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)Proceedings of the National Academy of Sciences, 1998
- Vascular endothelial growth factorJournal of Neuro-Oncology, 1997
- Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 ReceptorsJournal of Biological Chemistry, 1996
- Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites FluidScience, 1983